Fast-acting PEA mouth spray for chronic pain relief
Introducing a novel PEA mouth spray offering rapid relief from chronic and neuropathic pain through sublingual delivery, enhancing bioavailability and user convenience. This over-the-counter solution is non-psychoactive, with a strong safety profile and broad patent coverage.
Overview
The fast-acting PEA mouth spray developed by Eyesiu Medicines BV is a breakthrough in the management of chronic and neuropathic pain. By leveraging the bioavailability benefits of sublingual delivery, this innovative product offers consumers a more effective and convenient alternative to traditional PEA capsules, which often have low bioavailability. The spray harnesses the natural anti-inflammatory and neuroprotective properties of PEA, a well-documented endogenous fatty acid amide, providing rapid relief without the need for prolonged capsule ingestion.
Technical specifications
Key features:
- Proprietary solvent-free, stable lipid particle solution of PEA.
- Sublingual spray format for rapid systemic absorption and precise dosing.
- Non-psychoactive with a strong safety profile, avoiding regulatory hurdles of cannabinoids.
- Extensive patent protection in major markets including the USA, Taiwan, Russia, and others, valid until 2036.
- High customer retention demonstrated in initial market launch in the Netherlands.
Technology readiness level
The product is currently at Technology Readiness Level 6, indicating a prototype has been demonstrated in a relevant environment. Further developments are planned to enhance packaging, scale manufacturing, and expand distribution globally, leveraging existing regulatory approvals for ingredients and excipients.
About Eyesiu Medicines BV
Eyesiu Medicines BV, founded in 2014 and based at the Leiden Bio Science Park in the Netherlands, specializes in the development of innovative therapeutics and nutraceuticals. The company leverages advanced nanotechnology, specifically proprietary PEGylated lipid nanoparticle delivery technology, to improve the efficacy and delivery of existing therapeutics and body-own molecules. This technology allows for the creation of solvent-free, stable formulations that can be administered via various routes, including intranasal, ocular, dermal, and inhalation, targeting inflammatory processes across neurology, ophthalmology, dermatology, and pulmonology. The company differentiates its approach by using this platform to enhance the performance of established compounds for broader clinical applications.
These advancements are significant for addressing chronic inflammatory disorders and improving patient quality of life. By optimizing the delivery of molecules like cyclosporine A and palmitoylethanolamide (PEA), Eyesiu aims to provide more effective treatments for conditions affecting the brain, eyes, lungs, skin, and hair. In addition to its preclinical pharmaceutical pipeline, the company operates a consumer healthcare division, Eyesiu Care, which offers nutraceutical products like the PEArlboost+ spray. Eyesiu continues to expand its intellectual property portfolio through international patent grants for its lipid particle formulas and actively explores product partnerships to further its research and development initiatives.
Inquire about this partnering listing
Industry applications
delivered to your inbox.